JP2007527913A - イオンチャンネルモジュレーター - Google Patents

イオンチャンネルモジュレーター Download PDF

Info

Publication number
JP2007527913A
JP2007527913A JP2007502988A JP2007502988A JP2007527913A JP 2007527913 A JP2007527913 A JP 2007527913A JP 2007502988 A JP2007502988 A JP 2007502988A JP 2007502988 A JP2007502988 A JP 2007502988A JP 2007527913 A JP2007527913 A JP 2007527913A
Authority
JP
Japan
Prior art keywords
independently selected
cycloalkyl
optionally substituted
halogen
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007502988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527913A5 (https=
Inventor
ロバート・ゼル
ビンセント・ピー・ガルロ
ホーモズ・マズディヤズニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of JP2007527913A publication Critical patent/JP2007527913A/ja
Publication of JP2007527913A5 publication Critical patent/JP2007527913A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007502988A 2004-03-08 2005-03-07 イオンチャンネルモジュレーター Pending JP2007527913A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55137104P 2004-03-08 2004-03-08
PCT/US2005/007902 WO2005086895A2 (en) 2004-03-08 2005-03-07 Ion channel modulators

Publications (2)

Publication Number Publication Date
JP2007527913A true JP2007527913A (ja) 2007-10-04
JP2007527913A5 JP2007527913A5 (https=) 2008-04-24

Family

ID=34976220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007502988A Pending JP2007527913A (ja) 2004-03-08 2005-03-07 イオンチャンネルモジュレーター

Country Status (8)

Country Link
US (2) US7368467B2 (https=)
EP (1) EP1722783A4 (https=)
JP (1) JP2007527913A (https=)
CN (1) CN1946397A (https=)
AU (1) AU2005221131A1 (https=)
BR (1) BRPI0508556A (https=)
CA (1) CA2557648A1 (https=)
WO (1) WO2005086895A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527909A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
JP2007527919A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
JP2017533268A (ja) * 2014-10-29 2017-11-09 アポグリクス アクツィエブーラーグＡｐｏＧｌｙｘ ＡＢ 特に糖尿病の治療に有用である２−（１，２，４−トリアゾール−３−イルスルファニル）−ｎ−１，３，４−チアジアゾール−２−イルアセトアミドの誘導体

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558214A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20070208064A1 (en) * 2004-03-08 2007-09-06 Wyeth Ion channel modulators
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
EP1888575A2 (en) * 2005-05-09 2008-02-20 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
US7893260B2 (en) * 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
WO2008033564A1 (en) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
EP1939181A1 (en) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
EP3115045B1 (de) * 2008-08-26 2020-08-12 Basf Se Nachweis und verwendung niedermolekularer modulatoren des kälte-menthol-rezeptors trpm8
EA201100441A1 (ru) * 2008-09-04 2011-10-31 Ардеа Биосайнсиз, Инк. Соединения для коррекции уровня мочевой кислоты и способы их применения
WO2010101724A1 (en) * 2009-03-04 2010-09-10 Merck Sharp & Dohme Corp. Imidazole derivatives useful as modulators of faah and as faah imaging agents
WO2013054338A1 (en) * 2011-07-06 2013-04-18 Cadila Healthcare Limited 2-thio-imidazole derivatives as tgr5 modulators
WO2013102929A1 (en) * 2011-12-26 2013-07-11 Cadila Healthcare Limited Novel compounds for treatment of diabetes, obesity or related disorders
US20140235585A1 (en) * 2013-02-20 2014-08-21 Allergan, Inc. Substituted diaryl derivatives as sphingosine receptor modulators
EP4096661B1 (en) 2020-01-29 2025-04-02 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders
EP4377297A4 (en) * 2021-07-30 2025-05-28 The Regents of the University of California Compounds for modulating epithelial 15-(s)-lipoxygenase-2 and methods of use for same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527909A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734421A (en) * 1986-10-29 1988-03-29 Merck & Co., Inc. Anti-inflammatory substituted 2-benzyl-mercapto-imidazole and pyrimidine derivatives compositions and method of use therefor
EP0994858A1 (en) * 1997-06-30 2000-04-26 Ortho-McNeil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US20030199523A1 (en) * 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527909A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527909A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
JP2007527919A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
JP2017533268A (ja) * 2014-10-29 2017-11-09 アポグリクス アクツィエブーラーグＡｐｏＧｌｙｘ ＡＢ 特に糖尿病の治療に有用である２−（１，２，４−トリアゾール−３−イルスルファニル）−ｎ−１，３，４−チアジアゾール−２−イルアセトアミドの誘導体

Also Published As

Publication number Publication date
CA2557648A1 (en) 2005-09-22
EP1722783A4 (en) 2009-08-12
US20080090891A1 (en) 2008-04-17
WO2005086895A3 (en) 2006-08-17
WO2005086895A2 (en) 2005-09-22
BRPI0508556A (pt) 2007-08-07
EP1722783A2 (en) 2006-11-22
AU2005221131A1 (en) 2005-09-22
US7368467B2 (en) 2008-05-06
US20050203159A1 (en) 2005-09-15
CN1946397A (zh) 2007-04-11

Similar Documents

Publication Publication Date Title
JP2007527919A (ja) イオンチャンネルモジュレーター
US20080090891A1 (en) Ion channel modulators
JP2007527909A (ja) イオンチャンネルモジュレーター
JP2007527917A (ja) イオンチャンネルモジュレーター
JP2007527911A (ja) イオンチャンネルモジュレーター
JP2007527912A (ja) イオンチャンネルモジュレーター
JP2007527920A (ja) イオンチャンネルモジュレーター
JP2007527916A (ja) イオンチャンネルモジュレーター
JP2007527910A (ja) イオンチャンネルモジュレーター
JP2007527915A (ja) イオンチャンネルモジュレーター
MXPA06010036A (en) Ion channel modulators
MXPA06010022A (en) Ion channel modulators
MXPA06010034A (en) Ion channel modulators
MXPA06010038A (en) Ion channel modulators
MXPA06010037A (en) Ion channel modulators
MXPA06010033A (en) Ion channel modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018